Literature DB >> 17578484

Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging.

B J Van der Schueren1, J N de Hoon, F H Vanmolkot, A Van Hecken, M Depre, S A Kane, I De Lepeleire, S R Sinclair.   

Abstract

AIMS: Part I: to establish the dose and appropriate application site of capsaicin on the human forearm in order to produce a robust and reproducible dermal blood flow (DBF) response. Part II: to evaluate the within-subject arm-to-arm and period-to-period reproducibility.
METHODS: Both parts consisted of two study visits. In part I, placebo and 100, 300 and 1000 microg capsaicin were applied at four predefined sites on the volar surface of both forearms. Placebo and capsaicin doses were randomized and balanced by site between subjects. Changes in DBF were assessed by laser Doppler perfusion imaging up to 60 min after capsaicin application. In part II, only 1000 microg capsaicin was applied on the proximal forearm and changes in DBF assessed up to 30 min (t(30)). DBF response was expressed as percent change from baseline +/- SD and the corresponding AUC(0-30). Reproducibility assessment included calculation of the concordance correlation coefficient (CCC).
RESULTS: Part I (n = 12 subjects): compared with placebo, 300 and 1000 microg capsaicin increased DBF (P < 0.05) at all time points except at 10 min. This increase was reproducible at the two most proximal sites from the 30-min time point onwards when compared between arms (CCC >or= 0.8, i.e. substantial to almost perfect reproducibility). In part II (n = 11), t(30) averaged 390 +/- 120% and arm-to-arm reproducibility was almost perfect (CCC = 0.91) for AUC(0-30).
CONCLUSIONS: Capsaicin induces a reproducible within-subject arm-to-arm increase in DBF. We provide a non-invasive pharmacodynamic model in humans to test antagonists of mediators involved in capsaicin-induced dermal vasodilation, including calcitonin gene-related peptide antagonists.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17578484      PMCID: PMC2203262          DOI: 10.1111/j.1365-2125.2007.02939.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  51 in total

1.  Guidelines for measurement validation in clinical trial design.

Authors:  M M Sanchez; B S Binkowitz
Journal:  J Biopharm Stat       Date:  1999-08       Impact factor: 1.051

2.  Noxious heat activates all capsaicin-sensitive and also a sub-population of capsaicin-insensitive dorsal root ganglion neurons.

Authors:  I Nagy; H Rang
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

Review 3.  Vanilloid (Capsaicin) receptors and mechanisms.

Authors:  A Szallasi; P M Blumberg
Journal:  Pharmacol Rev       Date:  1999-06       Impact factor: 25.468

4.  Studies on the action potentials of sensory nerves in animals desensitized with capsaicine.

Authors:  J PORSZASZ; N JANCSO
Journal:  Acta Physiol Acad Sci Hung       Date:  1959

5.  The capsaicin receptor: a heat-activated ion channel in the pain pathway.

Authors:  M J Caterina; M A Schumacher; M Tominaga; T A Rosen; J D Levine; D Julius
Journal:  Nature       Date:  1997-10-23       Impact factor: 49.962

6.  The cloned capsaicin receptor integrates multiple pain-producing stimuli.

Authors:  M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

Review 7.  Vasoactive peptides in the skin.

Authors:  J Wallengren
Journal:  J Investig Dermatol Symp Proc       Date:  1997-08

8.  Aerobic exercise capacity remains normal despite impaired endothelial function in the micro- and macrocirculation of physically active IDDM patients.

Authors:  A Veves; R Saouaf; V M Donaghue; C A Mullooly; J A Kistler; J M Giurini; E S Horton; R A Fielding
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

9.  Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms.

Authors:  S J Morris; A C Shore
Journal:  J Physiol       Date:  1996-10-15       Impact factor: 5.182

10.  The effects of repeated dermal application of capsaicin to the human skin on pain and vasodilatation induced by intradermal injection of acid and hypertonic solutions.

Authors:  E Del Bianco; P Geppetti; P Zippi; D Isolani; B Magini; P Cappugi
Journal:  Br J Clin Pharmacol       Date:  1996-01       Impact factor: 4.335

View more
  11 in total

1.  Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.

Authors:  Henrik Winther Schytz; Helle Holst; Lars Arendt-Nielsen; Jes Olesen; Messoud Ashina
Journal:  J Headache Pain       Date:  2010-05-09       Impact factor: 7.277

Review 2.  Clinical pharmacology--providing tools and expertise for translational medicine.

Authors:  J K Aronson; A Cohen; L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

3.  Evaluation of a mobile NMR sensor for determining skin layers and locally estimating the T(2eff) relaxation time in the lower arm.

Authors:  Darius Kornetka; Martin Trammer; Jochen Zange
Journal:  MAGMA       Date:  2012-05-13       Impact factor: 2.310

4.  Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist.

Authors:  Chi-Chung Li; Steve Vermeersch; William S Denney; William P Kennedy; John Palcza; Adrianna Gipson; Tae H Han; Rebecca Blanchard; Inge De Lepeleire; Marleen Depré; M Gail Murphy; Kristien Van Dyck; Jan N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

Review 5.  Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model.

Authors:  Linde Buntinx; Steve Vermeersch; Jan de Hoon
Journal:  Br J Clin Pharmacol       Date:  2015-10-06       Impact factor: 4.335

6.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

7.  TRPV1 dysfunction in cystinosis patients harboring the homozygous 57 kb deletion.

Authors:  L Buntinx; T Voets; B Morlion; L Vangeel; M Janssen; E Cornelissen; J Vriens; J de Hoon; E Levtchenko
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

8.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.

Authors:  David Monteith; Emily C Collins; Corinne Vandermeulen; Anne Van Hecken; Eyas Raddad; Joel C Scherer; David Grayzel; Thomas J Schuetz; Jan de Hoon
Journal:  Front Pharmacol       Date:  2017-10-17       Impact factor: 5.810

9.  Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects.

Authors:  Thuy Vu; Peiming Ma; Jiyun Sunny Chen; Jan de Hoon; Anne Van Hecken; Lucy Yan; Liviawati Sutjandra Wu; Lisa Hamilton; Gabriel Vargas
Journal:  Pharm Res       Date:  2017-06-07       Impact factor: 4.200

10.  TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study.

Authors:  Prasarn Manitpisitkul; Michael Brandt; Christopher M Flores; Velga Kenigs; John A Moyer; Gary Romano; Kevin Shalayda; Arthur J Mayorga
Journal:  Pain Rep       Date:  2016-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.